Improving kidney repair after chemotherapy with a new treatment
Targeting Tubular Mitochondrial Superoxide Dismutation in Cisplatin Renal Repair
This study is looking at how a treatment called GC4419 can help protect kidney cells from damage caused by the chemotherapy drug Cisplatin, with the hope of improving kidney health for patients who have received this treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project ID | NIH-10979217 on NIH RePORTER |
What this research studies
This research focuses on how the chemotherapy drug Cisplatin can lead to chronic kidney disease by causing damage to kidney cells. The study investigates a treatment called GC4419, which aims to protect kidney cells from oxidative stress and improve their ability to repair after Cisplatin exposure. Researchers will explore how this treatment affects mitochondrial function and metabolism in kidney cells, and identify biomarkers that can predict its effectiveness. The goal is to enhance kidney recovery and function in patients who have received Cisplatin.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults who have received Cisplatin as part of their cancer treatment and are experiencing kidney issues.
Not a fit: Patients who have not received Cisplatin or those with pre-existing severe kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved kidney health and recovery for patients undergoing Cisplatin treatment.
How similar studies have performed: Previous research has shown promising results with similar antioxidant treatments in protecting kidney function, indicating potential for success in this approach.
Where this research is happening
Columbus, United States
- Research Inst Nationwide Children's Hosp — Columbus, United States (Active)
Researchers
- Principal investigator: Zepeda-Orozco, Diana — Research Inst Nationwide Children's Hosp
- Study coordinator: Zepeda-Orozco, Diana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.